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Abstract
A response to Parienti JJ, Verdon R and Massari V: Methodological standards in non-inferiority
AIDS trials: moving from adherence to compliance. BMC Med Res Meth 2006, 6:46
Text
Recently, Parienti et al. discussed in this journal the use of
non-inferiority studies in HIV research[1]. Given the avail-
ability of efficient combinations of antiretroviral drugs in
the first-line treatment of HIV-1 infection, such trials are
needed to thoroughly investigate novel drug combina-
tions for claims of added effectiveness. The design, analy-
sis and interpretation of non-inferiority trials is not
straightforward and a critical article on these issues is wel-
comed. Scientific debate about published data will stimu-
late progress in the use of non-inferiority studies in HIV
research. However, one has to be cautious that in this
debate the facts are presented correctly. Unfounded criti-
cisms will have a detrimental effect of downplaying the
original results leading to uncertainties about the true
effectiveness of the drugs involved. In our opinion the
results of the 2NN study were not adequately represented
in the article by Parienti et al. giving the impression that
the results and conclusions of the 2NN study should be
questioned.
The main purpose of the 2NN study was to compare four
different treatment strategies[2]. In two of the study
groups licensed drugs were used in an off-label manner. In
the two remaining groups the licensed drugs were used
according to the manufacturer's instructions. We were
adamant that only the comparison of drugs in the latter
groups (nevirapine [NVP] twice daily and efavirenz [EFV])
would be tested for equivalence. The study was powered
for this purpose only.
Parienti et al. present in Table 2 the results of two addi-
tional equivalence analyses using the 2NN data; between
the off-label use of NVP once daily and EFV, and between
the experimental regimen NVP+EFV and EFV. Not only is
this against the intention of the 2NN investigators, these
analyses only have around 60% power to demonstrate a
difference in efficacy that is smaller than 10% (the a-priori
set limit).
For the main comparison of the 2NN study Parienti et al.
present an equivalence analysis for an on-treatment pop-
ulation (OT) to make up for the absence of this analysis in
the original report. We agree with the authors that the use
of an OT analysis in an equivalence test has the smallest
risk of dilution of the results. However, because the 2NN
was an open-label study with change of treatment as one
of the components of treatment failure (the primary out-
come), an OT population could severely bias the out-
come. Unfortunately, the data that the authors use to
Published: 2 March 2007
BMC Medical Research Methodology 2007, 7:14 doi:10.1186/1471-2288-7-14
Received: 20 October 2006
Accepted: 2 March 2007
This article is available from: http://www.biomedcentral.com/1471-2288/7/14
© 2007 van Leth et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Research Methodology 2007, 7:14 http://www.biomedcentral.com/1471-2288/7/14
Page 2 of 3
(page number not for citation purposes)
perform this analysis are not from an OT population but
from the population that completed the 48 weeks of fol-
low-up. This population is a mix of those who are still on
their allocated treatment and those who are not. Deduc-
ing the number of patients changing allocated treatment
(and arriving at the OT-population) from the reasons for
treatment failure is misplaced due to the 'competing risks'
inherent to the composite primary outcome[3]. The dif-
ference in efficacy between NVP twice daily and EFV of
7.7% with an upper limit of the confidence interval of
14.6% that the authors present as the OT-analysis is from
the intention-to-treat population excluding the patients
who did not take any study drug.
We do agree with the authors that our wording in the con-
clusion of the abstract and the body of the manuscript, is
ambiguous and might be misinterpreted. For the main
comparison (equivalence between NVP twice daily and
EFV), we report throughout the discussion that the differ-
ence between NVP twice daily and EFV was not signifi-
cantly different ('similar') in a head-to-head comparison,
but that equivalence of the two strategies could not be
demonstrated. It would have been clearer to refrain from
the term 'similar' in this respect and stick to the terminol-
ogy that fits the equivalence design of the study. We used
this wording to incorporate the conventional superiority
analysis and the clinical interpretation of the results. The
relatively small differences in primary and secondary effi-
cacy endpoint of the study (treatment failure, percentage
undetectable, CD4 increase) and the absence of large dif-
ferences in the incidence of adverse events make that we
see nevirapine and efavirenz as indeed interchangeable
drugs, despite the lack of formal equivalence in the pri-
mary efficacy outcome.
Having said this, Parienti et al. report in their Table 2 that
we used the same confusing terminology for the other
equivalent analyses. This is not the case and does not do
justice to the 2NN study. We never performed other
equivalence analyses than for the primary comparison.
We would also like to make a more theoretical note. A
non-inferiority design and an equivalence design are
closely linked but the underlying idea is fundamentally
different and goes beyond the type of confidence interval
used as described by Parienti et al. In a non-inferiority
study the main question is to assess whether a new drug is
not worse off than the current standard of care. In this sit-
uation there is no room for the new drug to show superior
activity. As a result, only the lower limit of the confidence
interval around the difference between the drugs com-
pared is of interest. In an equivalence study there is a-pri-
ory a situation of equipoise with respect to the efficacy of
two drugs. Although the main aim is to test whether the
two drugs have equivalent efficacy and can therefore be
used interchangeably, there is room for each of the drugs
to outperform the other. Therefore, both sides of the con-
fidence interval are of interest. For this reason we chose for
an equivalence study. NVP and EFV were widely used at
the time the study was conducted. Without a previous ran-
domized comparison between the two drugs, there was no
formal golden standard against which non-inferiority
should be tested, although in general EFV was believed to
be more effective than NVP based on data from observa-
tional cohort studies.
A critical appraisal of published results from studies on
the efficacy of antiretroviral drugs is most welcome since
it feeds the scientific debate and points out over-interpre-
tation of the results by investigators or drug companies.
However, misrepresentation of results and conclusions of
the original studies in this debate will undermine the
credibility of these studies with HIV-researchers and clini-
cal practitioners. An easy way to avoid this from happen-
ing is to contact the authors of the original studies to
provide the appropriate details. If such a strategy would
have been followed here, the review of Parienti et al could
have contributed more to this debate.
List of abbreviations used





All authors have received honorarium for lectures and
travel grants from different pharmaceutical companies,
including Boehringer Ingelheim (the manufacturer of
nevirapine) and Bristol-Myers Squibb (the manufacturer
of efavirenz)
Authors' contributions
FvL wrote the first draft and subsequent versions of the
manuscript.
FWW and JMA contributed to all versions of the manu-
script.
All authors approved the final version of the manuscript.
References
1. Parienti JJ, Verdon R, Massari V: Methodological standards in
non-inferiority AIDS trials: moving from adherence to com-
pliance.  BMC Med Res Methodol 2006, 6:46.
2. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard
B, Cahn P, Lalloo UG, van der Westhuizen JP, Malan DR, Johnson MA,
Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K,
Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP,Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Research Methodology 2007, 7:14 http://www.biomedcentral.com/1471-2288/7/14
Page 3 of 3
(page number not for citation purposes)
Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JMA: Com-
parison of first-line antiretroviral therapy with regimens
including nevirapine, efavirenz, or both drugs, plus stavudine
and lamivudine: a randomised open-label trial, the 2NN
Study.  Lancet 2004, 363(9417):1253-63.
3. van Leth F, Lange JM: Use of composite end points to measure
clinical events.  JAMA 2003, 290(11):1456-7. author reply 1457
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2288/7/14/prepub